期刊文献+

腹膜后淋巴结状态在卵巢癌治疗管理中的研究进展 被引量:1

下载PDF
导出
摘要 卵巢癌的发病率位于女性常见生殖道恶性肿瘤的第3位,死亡率居第一,由于大部分卵巢癌患者在初次发现确诊时已到晚期.美国癌症协会(ACS)报道,2019年美国约有2,2530例新发卵巢癌患者,其中约有1,3980例死亡^([1]).腹膜后淋巴结转移是卵巢癌的常见转移方式之一,影响分期及预后.与相同手术病理分期的其他卵巢癌相比,腹膜后淋巴结转移的卵巢癌表现出明显的预后优势^([2-8]),2014年,国际妇产科联盟(FIGO)重新修订了卵巢癌分期,将仅有腹膜后淋巴结转移而无腹膜受累的卵巢癌分期至ⅢA1期^([9]).
出处 《浙江临床医学》 2021年第4期588-591,共4页 Zhejiang Clinical Medical Journal
基金 浙江省医药卫生一般研究计划(A类)(2014KYA010) 浙江省中医药优秀青年人才基金项目(201820009)。
  • 相关文献

参考文献1

二级参考文献21

  • 1International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Accessed in 2015. Available online: http://globocan.iarc.fr/Pages/fact_ sheets_population.aspx.
  • 2Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
  • 3Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta- analysis. J Clin Oncol 2002;20:1248-59.
  • 4Peiretti M, Zanagnolo V, Aletti GD, et al. Role of maximal primary cytoreductive surgery in patients with advanced epithelial ovarian and tubal cancer: Surgical and oncological outcomes. Single institution experience. Gynecol Oncol 2010;119:259-64.
  • 5Chi DS, Venkatraman ES, Masson V, et al. The ability of preoperative serum CA-125 to predict optimal primary tumor cytoreduction in stage III epithelial ovarian carcinoma. Gynecol Oncol 2000;77:227-31.
  • 6Chi DS, Zivanovic O, Palayekar MJ, et al. A contemporary analysis of the ability of preoperative serum CA-125 to predict primary cytoreductive outcome in patients with advanced ovarian, tubal and peritoneal carcinoma. Gynecol Oncol 2009;112:6-10.
  • 7Vorgias G, Iavazzo C, Savvopoulos P, et al. Can the preoperative Ca-125 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? A single institution cohort study. Gynecol Oncol 2009;112:11-5.
  • 8Angioli R, Plotti F, Capriglione S, et al. Can the preoperative HE4 level predict optimal cytoreduction in patients with advanced ovarian carcinoma? Gynecol Oncol 2013;128:579-83.
  • 9Barlow TS, Przybylski M, Schilder JM, et al. The utility of presurgical CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. IntJ Gynecol Cancer 2006;16:496-500.
  • 10Drapkin R, von Horsten HH, Lin Y, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res 2005;65:2162-9.

共引文献9

同被引文献20

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部